Úprava vyjádření síly u léčivého přípravku CAMPRAL 300 mg enterosolventní tablety

The State Institute for Drug Control (SÚKL) approved a change in the registration of the medicinal product CAMPRAL as of May 22, 2026, concerning the adjustment of how its strength is expressed. Originally, the strength was expressed as 300 mg, corresponding to the amount of acamprosate. Now, the strength will be expressed as 333 mg, representing the amount of acamprosate calcium salt. SÚKL emphasizes that there has been no change in the actual content of the active substance in the product. The quantitative content remains the same, with 333 mg of acamprosate calcium salt being equivalent to 300 mg of acamprosate. This adjustment will be reflected in the product's name, database records, and prescription software applications. The change has no impact on the recommended dosage or the way the product is used.